12:00 AM
 | 
Mar 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIT225: Phase II ongoing

Biotron began enrollment of a second set of 12 patients in a double-blind, placebo-controlled, Thai Phase II trial to evaluate 200 or 400 mg BIT225 in...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >